ICUI on XNAS, Health Care, ICU Medical Inc, job postings
Measures activity, not value. Not investment advice.
Twelve-month revenue fell 5.9% to $2.2B while the stock rose 28% in twelve months.
WatchCapital spending down 44% to $16.2M in the latest quarter
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
Industry
Surgical & medical instruments & apparatus (Health Care)
expected around 18 Feb 2027 (an estimate: a year ago it reported on 19 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $560.4M, net income $26.8M.
31 Mar 2022RevenueNet incomeNet losstallest bar $604.7M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$560.4M
$26.8M
30 Jun 2026
$551.7M
$19.1M
31 Mar 2026
$530.2M
$30.1M
30 Sep 2025
$537.0M
-$3.4M
30 Jun 2025
$548.9M
$35.3M
31 Mar 2025
$604.7M
-$15.5M
30 Sep 2024
$589.1M
-$33.0M
30 Jun 2024
$596.5M
-$21.4M
31 Mar 2024
$566.7M
-$39.5M
30 Sep 2023
$553.3M
$7.2M
30 Jun 2023
$549.3M
-$9.9M
31 Mar 2023
$568.6M
-$9.8M
30 Sep 2022
$597.9M
-$13.2M
30 Jun 2022
$561.0M
-$7.5M
31 Mar 2022
$543.1M
-$38.1M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$2.2B
$2.3B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
-5.9%
+13%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$60.3M
-$7.4M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$2.40
-$0.32
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
40.3%
36.5%
60.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
5.1%
3.2%
-8.3%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
2.8%
-0.3%
-10.1%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
2.8%
-26.3%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$208.6M
$72.0M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$301.8M
$299.7M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$1.2B
$1.3B
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$850.1M
$1.0B
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.53
0.31
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$87.62
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
71.5
28.0
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
2.0
2.3
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
2.4
2.5
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
2.0
2.8
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$4.0M
bought $0, sold $4.0M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+9.9%
311 13F filers vs 283
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
25.3M shares held by 13F filers (30 Sep 2026) of 25.0M outstanding (31 Oct 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
6.7%
1.7M shares sold short (30 Oct 2026) of 25.0M outstanding (31 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
8.0
1.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-2.4%
1.7M shares sold short in the report before, 1.7M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
69%
69% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 62%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
+8.0%
27 vs 25 applications
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+4.4%
$560.4M vs $537.0M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-44%
$16.2M vs $29.1M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
25
25 articles in the last 7 days; its usual week has 1.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
17×
25 articles in the last 7 days; its usual week has 1.5.
Price $172.52 on 20 Nov 2026, +28% over 12 months (12-month range $115.45 to $187.26)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $8.0M in the last 12 months (the 12 months before: -$8.3M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 27 published in the last 12 months, +8.0% on the 12 months before.Revenue per quarter. Revenue $560.4M in the latest quarter, +4.4% on a year earlier.Capital spending per quarter. Capital spending $16.2M in the latest quarter, -44% on a year earlier.Institutional holders (13F filers). 311 13F filers reported holding it in the latest 13F quarter, +21% on a year earlier.Federal obligations. Federal obligations: $63K published in the last 12 months, +117% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: lobbying spend, workers in warn layoff notices.
Quarter ended 31 Mar 2022: $543.1M, +71% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $561.0M, +74% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $597.9M, +78% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Mar 2023: $568.6M, +4.7% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $549.3M, -2.1% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $553.3M, -7.5% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Mar 2024: $566.7M, -0.4% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $596.5M, +8.6% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $589.1M, +6.5% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Mar 2025: $604.7M, +6.7% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $548.9M, -8.0% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $537.0M, -8.9% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Mar 2026: $530.2M, -12% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $551.7M, +0.5% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $560.4M, +4.4% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $22.1M, -26% on a year earlier; public on 26 Feb 2022
Quarter ended 31 Mar 2022: $23.6M, +68% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $24.4M, +56% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $20.7M, +23% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $21.6M, -2.2% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $14.2M, -40% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $18.3M, -25% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $21.5M, +3.8% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $29.9M, +39% on a year earlier; public on 28 Feb 2024
Quarter ended 31 Mar 2024: $15.9M, +12% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $19.5M, +6.5% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $19.9M, -7.3% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $24.1M, -20% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $14.6M, -8.1% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $19.7M, +1.2% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $29.1M, +46% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $24.6M, +2.3% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $11.3M, -23% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $18.5M, -6.0% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $16.2M, -44% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 263; public on 14 Feb 2022
31 Mar 2022 report: 274; public on 16 May 2022
30 Jun 2022 report: 241; public on 15 Aug 2022
30 Sep 2022 report: 218; public on 14 Nov 2022
31 Dec 2022 report: 222; public on 14 Feb 2023
31 Mar 2023 report: 216; public on 15 May 2023
30 Jun 2023 report: 210; public on 14 Aug 2023
30 Sep 2023 report: 201; public on 14 Nov 2023
31 Dec 2023 report: 227; public on 14 Feb 2024
31 Mar 2024 report: 239; public on 15 May 2024
30 Jun 2024 report: 241; public on 14 Aug 2024
30 Sep 2024 report: 272; public on 14 Nov 2024
31 Dec 2024 report: 281; public on 14 Feb 2025
31 Mar 2025 report: 270; public on 15 May 2025
30 Jun 2025 report: 264; public on 14 Aug 2025
30 Sep 2025 report: 258; public on 14 Nov 2025
31 Dec 2025 report: 279; public on 17 Feb 2026
31 Mar 2026 report: 267; public on 15 May 2026
30 Jun 2026 report: 283; public on 14 Aug 2026
30 Sep 2026 report: 311; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $279 published
Month from 1 Jan 2022: $1K published
Month from 1 Feb 2022: $134K published
Month from 1 Mar 2022: $83K published
Month from 1 Apr 2022: $2K published
Month from 1 May 2022: $551K published
Month from 1 Jun 2022: $91K published
Month from 1 Aug 2022: $80.4 published
Month from 1 Sep 2022: $22K published
Month from 1 Oct 2022: $5.5M published
Month from 1 Nov 2022: -$5K published
Month from 1 Dec 2022: $498 published
Month from 1 Jan 2023: $159 published
Month from 1 Feb 2023: -$28K published
Month from 1 Mar 2023: $13K published
Month from 1 May 2023: $8K published
Month from 1 Jun 2023: $214K published
Month from 1 Jul 2023: -$743K published
Month from 1 Aug 2023: $185K published
Month from 1 Sep 2023: -$270 published
Month from 1 Oct 2023: $50K published
Month from 1 Apr 2024: $675 published
Month from 1 Jun 2024: $6K published
Month from 1 Nov 2024: $0 published
Month from 1 Jan 2025: -$6K published
Month from 1 May 2025: $34K published
Month from 1 Feb 2026: -$81.6 published
Month from 1 May 2026: -$14K published
Month from 1 Nov 2026: $77K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $156K (20 Nov 2026), 63% below its normal reading of $421K; higher than 17% of its own history.
Short interest spike: had 1.8M shares sold short in the 29 May 2026 report, 1.7× the same report last year Public on 10 Jun 2026.
Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response
$3.2M
HIGH ACUITY KIT (HAK) INFUSION PUMPS AND DISPOSABLES IN ACCORDANCE WITH ICU MEDICAL PROPOSAL DATED 4/3/2020, PUMPS SNS PROPOSAL HIGH ACUITY KIT - 300 BEDS.
Reported lobbying spend: $10K in Q1 2014, $20K in Q4 2013. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Two or more unrelated kinds of records unusual within 30 days
8 Nov 2022confirmed
Confirmed across sources Government contracts and Filings + Financials
ICU Medical(ICUI): booked $5.5M in federal contract and grant obligations in September 2022, 19,539× the same month last year, while it reported revenue of $597.9M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year. Two unrelated kinds of activity within 28 days.
Government contracts: Federal obligations jump, became public on 6 Oct 2022
Financials: Quarterly revenue change, became public on 8 Nov 2022
September 2022 against the 5 months before it.
this monthearliernormal: $25KSee the evidence (2 changes)
Government contracts: Federal obligations jump became public on 6 Oct 2022
ICU Medical booked $5.5M in federal contract and grant obligations in September 2022, 19,539× the same month last year.
This period
$5.5M (September 2022)
Normal month (median of 5 earlier)
$25K
Typical spread (median absolute deviation)
$9K
How far from its usual level
+5.4
Same month last year
$279
History used
5,461 days
September 20225 earlier monthsnormal: $25K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Financials: Quarterly revenue change became public on 8 Nov 2022
ICU Medical reported revenue of $597.9M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year.
This period
$597.9M (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
$328.9M
Typical spread (median absolute deviation)
$10.6M
How far from its usual level
+8.2
Same quarter last year
$336.1M
History used
5,296 days
the quarter ended 30 Sep 20228 earlier quartersnormal: $328.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
10 Jun 2026Short interest and volume change
had 1.8M shares sold short in the 29 May 2026 report, 1.7× the same report last year.
Same report last year: 1.1M; its normal report is 1.3M.
See the evidence
This period
1.8M (the 29 May 2026 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
89K
How far from its usual level
+4.1
Same report last year
1.1M
History used
3,073 days
the 29 May 2026 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $578.0M for the quarter ended 31 Dec 2022, 1.7× the same quarter last year.
Same quarter last year: $340.5M; its normal quarter is $338.3M.
See the evidence
This period
$578.0M (the quarter ended 31 Dec 2022)
Normal quarter (median of 8 earlier)
$338.3M
Typical spread (median absolute deviation)
$19.0M
How far from its usual level
+7.1
Same quarter last year
$340.5M
History used
5,388 days
the quarter ended 31 Dec 20228 earlier quartersnormal: $338.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
booked $5.5M in federal contract and grant obligations in September 2022, 19,539× the same month last year, while it reported revenue of $597.9M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year. Two unrelated kinds of activity within 28 days.
See the evidence (2 changes)
Government contracts: Federal obligations jump became public on 6 Oct 2022
ICU Medical booked $5.5M in federal contract and grant obligations in September 2022, 19,539× the same month last year.
This period
$5.5M (September 2022)
Normal month (median of 5 earlier)
$25K
Typical spread (median absolute deviation)
$9K
How far from its usual level
+5.4
Same month last year
$279
History used
5,461 days
September 20225 earlier monthsnormal: $25K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Financials: Quarterly revenue change became public on 8 Nov 2022
ICU Medical reported revenue of $597.9M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year.
This period
$597.9M (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
$328.9M
Typical spread (median absolute deviation)
$10.6M
How far from its usual level
+8.2
Same quarter last year
$336.1M
History used
5,296 days
the quarter ended 30 Sep 20228 earlier quartersnormal: $328.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
8 Nov 2022Financials change
reported revenue of $597.9M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year.
Same quarter last year: $336.1M; its normal quarter is $328.9M.
See the evidence
This period
$597.9M (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
$328.9M
Typical spread (median absolute deviation)
$10.6M
How far from its usual level
+8.2
Same quarter last year
$336.1M
History used
5,296 days
the quarter ended 30 Sep 20228 earlier quartersnormal: $328.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
booked $5.5M in federal contract and grant obligations in September 2022, 19,539× the same month last year.
Same month last year: $279; its normal month is $25K.
See the evidence
This period
$5.5M (September 2022)
Normal month (median of 5 earlier)
$25K
Typical spread (median absolute deviation)
$9K
How far from its usual level
+5.4
Same month last year
$279
History used
5,461 days
September 20225 earlier monthsnormal: $25K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
reported revenue of $561.0M for the quarter ended 30 Jun 2022, 1.7× the same quarter last year.
Same quarter last year: $321.7M; its normal quarter is $321.1M.
See the evidence
This period
$561.0M (the quarter ended 30 Jun 2022)
Normal quarter (median of 8 earlier)
$321.1M
Typical spread (median absolute deviation)
$9.0M
How far from its usual level
+7.5
Same quarter last year
$321.7M
History used
5,204 days
the quarter ended 30 Jun 20228 earlier quartersnormal: $321.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $543.1M for the quarter ended 31 Mar 2022, 1.7× the same quarter last year.
Same quarter last year: $318.0M; its normal quarter is $321.1M.
See the evidence
This period
$543.1M (the quarter ended 31 Mar 2022)
Normal quarter (median of 8 earlier)
$321.1M
Typical spread (median absolute deviation)
$5.3M
How far from its usual level
+6.9
Same quarter last year
$318.0M
History used
5,113 days
the quarter ended 31 Mar 20228 earlier quartersnormal: $321.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 706K shares sold short in the 30 Jul 2021 report, 2.9× the same report last year.
Same report last year: 243K; its normal report is 317K.
See the evidence
This period
706K (the 30 Jul 2021 report)
Normal report (median of 24 earlier)
317K
Typical spread (median absolute deviation)
56K
How far from its usual level
+4.7
Same report last year
243K
History used
1,309 days
the 30 Jul 2021 report24 earlier reportsnormal: 317K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 553K shares sold short in the 15 Jul 2021 report, 2.0× the same report last year.
Same report last year: 270K; its normal report is 308K.
See the evidence
This period
553K (the 15 Jul 2021 report)
Normal report (median of 24 earlier)
308K
Typical spread (median absolute deviation)
45K
How far from its usual level
+3.7
Same report last year
270K
History used
1,294 days
the 15 Jul 2021 report24 earlier reportsnormal: 308K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Fires on an 8-K with item 5.02 after 90 days without one.
Showing the newest 40 of 60 entries; narrow the window or the kind of data to see older ones.
Not listed: 278 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0000883984
Ticker
ICUI
Domain
icumed.com
Employer name
ICU Medical, Inc., ICU Medical Sales, Inc. (2 unverified)
Fein
06-1211921 (1 unverified)
Hq location
CA|SAN CLEMENTE|92763 (1 unverified)
Lobbying client
icu medical
Name
Excelsior Medical Corporation, EXC Holding Corp, ICU Medical 2020 Limited, ICU Medical Argentina S.R.L and 59 more
Uei
G2WSBX6JWKB5, MKGHE5M8ANQ7
Wikidata
Q5969799
Wikipedia
ICU Medical
DOL H-1B labor condition applications and PERM certifications630 data points7 Oct 2019 to 28 Sep 2026
Federal lobbying disclosures (LDA)2 records, 12 data points10 Dec 2013 to 31 Dec 2014
SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)132 records11 Jan 2016 to 5 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1334 data points31 Dec 2006 to 31 Oct 2026
SEC Form 4 insider transactions180 records, 644 data points5 Jan 2016 to 20 Nov 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards2 records, 1341 data points18 Oct 2007 to 25 Sep 2026
Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026